Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 13 April Researchers load CAR-T cells with Oncolytic virus

<< Previous

Bullboard Posts

Next >>

Post by askretkaon Apr 13, 2022 11:07pm

306 Views

Post# 34602640

13 April Researchers load CAR-T cells with Oncolytic virus

https://www.sciencedaily.com/releases/2022/04/220413141538.htm ---------------------------------- Date:April 13, 2022Source:Mayo ClinicSummary:Researchers have devised an immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals